Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 16/20 | 0.79 |
| ▸ | TACR3 | P29371 | 17/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5733958 | 0.88 | TACR2 (1.00) | TACR2TACR3OPRM1KCNH2TRPV4 | |
| SCHEMBL6268770 | 0.88 | TACR3 (0.62) | TACR2TACR3OPRM1KCNH2TRPV4 | |
| SCHEMBL5734797 | 0.85 | TACR2 (1.00) | TACR2TACR3OPRM1KCNH2TRPV4 | |
| SCHEMBL3963977 | 0.85 | TACR2 (0.86) | TACR2TACR3OPRM1KCNH2TRPV4 | |
| SCHEMBL3962728 | 0.85 | TACR2 (0.79) | TACR2TACR3OPRM1KCNH2TRPV4 | |
| SCHEMBL5733338 | 0.85 | TACR2 (0.79) | TACR2TACR3OPRM1KCNH2TRPV4 | |
| SCHEMBL5733729 | 0.84 | TACR2 (0.81) | TACR2TACR3OPRM1KCNH2TRPV4 | |
| Hydrochloric Acid SCHEMBL5732533 | 0.84 | TACR2 (0.77) | TACR2TACR3OPRM1KCNH2TRPV4 | |
| SCHEMBL5733965 | 0.84 | TACR2 (0.77) | TACR2TACR3OPRM1KCNH2TRPV4 | |
| SCHEMBL27577059 | 0.80 | TACR2 (0.68) | TACR2TACR3OPRM1KCNH2TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482457-B2 | Substituted quinoline-4-carboxylic hydrazides as NK-2/NK-3 receptor ligands | MERCK SHARP & DOHME | 2009-01-27 | — | — | US | claimed |
| US-20060089348-A1 | Substituted quinoline-4-carboxylic hydrazides as nk-2/nk-3 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2006-04-27 | — | — | US | claimed |
| US-7482457-B2 | Substituted quinoline-4-carboxylic hydrazides as NK-2/NK-3 receptor ligands | MERCK SHARP & DOHME | 2009-01-27 | — | — | US | disclosed |
| US-20070203119-A1 | Combination Therapy For The Treatment Of Schizophrenia | MERCK SHARPE & DOHME LIMITED (GB) | 2007-08-30 | — | — | US | disclosed |
| EP-1778287-A2 | COMBINATION THERAPY WITH NK3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA | MERCK SHARP & DOHME LTD. (GB) | 2007-05-02 | — | — | EP | disclosed |
| US-20060089348-A1 | Substituted quinoline-4-carboxylic hydrazides as nk-2/nk-3 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2006-04-27 | — | — | US | disclosed |
| WO-2006016192-A2 | COMBINATION THERAPY WITH NK3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA | MERCK SHARP & DOHME LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| EP-1594844-A1 | SUBSTITUTED QUINOLINE-4-CARBOXYLIC HYDRAZIDES AS NK-2/NK-3 RECEPTOR LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004072045-A1 | SUBSTITUTED QUINOLINE-4-CARBOXYLIC HYDRAZIDES AS NK-2/NK-3 RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089348-A1 | Substituted quinoline-4-carboxylic hydrazides as nk-2/nk-3 receptor ligands | HRH4, HRH3, HRH2 | TACR2 6/4885TACR3 8/4885OPRM1 370/4885 |
| US-20070203119-A1 | Combination Therapy For The Treatment Of Schizophrenia | HTR3B, HTR3A, TACR2 | TACR2 3/4885TACR3 15/4885OPRM1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.